L. Andrews

Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis

S. Bartz, D. Johns, S. Yendluri, 2015, Journal of Cardiovascular Translational Research.

Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension

S. Bartz, D. Cully, Marianne E. Eybye, 2014, Hypertension Research.

siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids[S]

S. Bartz, Kenny K. Wong, L. Mitnaul, 2011, Journal of Lipid Research.